Related Experiment Video
Updated: Sep 21, 2025
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets
Samuel Swearson1, Aseel O Rataan2, Steven Eliason1
1Department of Anatomy and Cell Biology, Craniofacial Anomalies Research Center, The University of Iowa, Iowa City, IA 52242, USA.
Abstract:
This study was carried out to quantitate the expression levels of microRNA-17, -19a, -34a, -155, and -210 (miRs) expressed in nine clear cell renal cell carcinoma (ccRCC) and one chromophobe renal cell carcinoma cell line with and without sarcomatoid differentiation, and in six primary kidney tumors with matching normal kidney tissues. The data in the five non-sarcomatoid ccRCC cell lines-RC2, CAKI-1, 786-0, RCC4, and RCC4/VHL-and in the four ccRCC with sarcomatoid differentiation-RCJ41T1, RCJ41T2, RCJ41M, and UOK-127-indicated that miR-17 and -19a were expressed at lower levels relative to miR-34a, -155, and -210. Compared with RPTEC normal epithelial cells, miR-34a, miR-155, and miR-210 were expressed at higher levels, independent of the sarcomatoid differentiation status and hypoxia-inducible factors 1α and 2α (HIFs) isoform expression. In the one chromophobe renal cell carcinoma cell line, namely, UOK-276 with sarcomatoid differentiation, and expressing tumor suppressor gene TP53, miR-34a, which is a tumor suppressor gene, was expressed at higher levels than miR-210, -155, -17, and -19a. The pilot results generated in six tumor biopsies with matching normal kidney tissues indicated that while the expression of miR-17 and -19a were similar to the normal tissue expression profile, miR-210, -155, -and 34a were expressed at a higher level. To confirm that differences in the expression levels of the five miRs in the six tumor biopsies were statistically significant, the acquisition of a larger sample size is required. Data previously generated in ccRCC cell lines demonstrating that miR-210, miR-155, and HIFs are druggable targets using a defined dose and schedule of selenium-containing molecules support the concept that simultaneous and concurrent downregulation of miR-210, miR-155, and HIFs, which regulate target genes associated with increased tumor angiogenesis and drug resistance, may offer the potential for the development of a novel mechanism-based strategy for the treatment of patients with advanced ccRCC.
Insights
This study quantifies microRNA (miR) expression in kidney cancer cell lines and tumors. Higher levels of miR-34a, miR-155, and miR-210 were observed in clear cell renal cell carcinoma (ccRCC), suggesting potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRs) play crucial roles in cellular processes and cancer development.
- Specific miRs, including miR-17, -19a, -34a, -155, and -210, are implicated in renal cell carcinoma (RCC).
- Understanding miR expression patterns in different RCC subtypes and differentiation states is vital for targeted therapies.
Purpose of the Study:
- To quantify the expression levels of five specific microRNAs (miRs) in clear cell renal cell carcinoma (ccRCC) and chromophobe renal cell carcinoma cell lines.
- To compare miR expression in cancer cell lines with and without sarcomatoid differentiation.
- To analyze miR expression in primary kidney tumors relative to matched normal kidney tissues.
Main Methods:
- Quantitative analysis of microRNA expression using cell lines and primary tumor samples.
- Comparison of miR levels across different RCC subtypes (ccRCC, chromophobe RCC) and differentiation statuses (sarcomatoid vs. non-sarcomatoid).
- Assessment of miR expression relative to normal kidney epithelial cells (RPTEC) and normal kidney tissues.
Main Results:
- In ccRCC cell lines, miR-17 and -19a were expressed at lower levels compared to miR-34a, -155, and -210.
- miR-34a, miR-155, and miR-210 showed higher expression in ccRCC cell lines than in normal RPTEC cells, irrespective of sarcomatoid differentiation or HIF expression.
- Primary kidney tumor samples indicated elevated levels of miR-210, -155, and -34a compared to normal kidney tissue.
Conclusions:
- Specific microRNAs (miR-34a, miR-155, miR-210) are consistently upregulated in renal cell carcinoma.
- These upregulated miRs, along with hypoxia-inducible factors (HIFs), represent potential druggable targets for advanced ccRCC treatment.
- Targeting these miRs and HIFs could offer a novel mechanism-based therapeutic strategy for ccRCC patients, potentially impacting tumor angiogenesis and drug resistance.
